Healthcare -
Biotechnology - NASDAQ - US
$ 28.98
-14.9 %
$ 1.88 B
Market Cap
-9.59
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Kymera Therapeutics, Inc.
| Revenue | 47.1 M |
| Cost Of Revenue | 7.37 M |
| Gross Profit | 39.7 M |
| Operating Expenses | 309 M |
| Operating Income | -262 M |
| Other Expenses | -37.8 M |
| Net Income | -224 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 47.1 | 78.6 | 46.8 | 72.8 | 34.0 | 2.9 | 0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 7.4 | 189.1 | 3.0 | 2.4 | 62.1 | 0.8 | 0.2 |
| Gross Profit | 39.7 | (110.5) | 43.8 | 70.4 | (28.1) | 2.1 | (0.2) |
| OPERATING INCOME | |||||||
| Operating Expenses | 308.7 | 244.1 | 208.1 | 173.4 | 80.3 | 45.1 | 21.5 |
| Selling, General and Administrative Expenses | 63.5 | 55.0 | 43.8 | 36.3 | 18.2 | 8.0 | 3.8 |
| Research and Development Expenses | 240.2 | 189.1 | 164.2 | 137.0 | 62.1 | 37.2 | 17.7 |
| Operating Income | (261.6) | (165.5) | (161.3) | (100.5) | (46.3) | (42.2) | (21.5) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 46 K | 16 K |
| Total Other Income | 37.8 | 18.6 | 6.4 | 0.3 | 0.7 | 1.0 | 16 K |
| Pre-Tax Income | (223.9) | (147.0) | (154.8) | (100.2) | (45.6) | (41.2) | (21.5) |
| NET INCOME | |||||||
| Tax Provision | 0 | 0 | (3.0) | (2.2) | (1.6) | 46 K | 43.9 K |
| Net Income | (223.9) | (147.0) | (151.8) | (98.0) | (43.9) | (41.3) | (21.5) |
| EPS | 2.98 | 2.52 | 2.82 | 2.04 | 2.53 | 0.93 | 0.48 |